Pretransplant comorbidities predict severity of acute graft-versus-host disease and subsequent mortality-Reference-Cited by-同舟云学术

Pretransplant comorbidities predict severity of acute graft-versus-host disease and subsequent mortality

Published:2014-07-10 Issue:2 Volume:124 Page:287-295
ISSN:0006-4971
Container-title:Blood
language:en
Short-container-title:

Author:

Sorror Mohamed L.¹²^ORCID,Martin Paul J.¹²^ORCID,Storb Rainer F.¹²^ORCID,Bhatia Smita³^ORCID,Maziarz Richard T.⁴⁵^ORCID,Pulsipher Michael A.⁶⁷,Maris Michael B.⁸,Davis Christopher¹,Deeg H. Joachim¹²^ORCID,Lee Stephanie J.¹²^ORCID,Maloney David G.¹²^ORCID,Sandmaier Brenda M.¹²^ORCID,Appelbaum Frederick R.¹²^ORCID,Gooley Theodore A.⁹¹⁰^ORCID

Affiliation:

1. Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA;

2. Division of Medical Oncology, Department of Medicine, University of Washington School of Medicine, Seattle, WA;

3. City of Hope School of Medicine, Duarte, CA;

4. Center for Hematologic Malignancies, Knight Cancer Institute, and

5. Division of Hematology and Medical Oncology, Oregon Health and Science University Knight Cancer Institute, Portland, OR;

6. Division of Hematology, University of Utah School of Medicine, Salt Lake City, UT;

7. Pediatric Blood and Marrow Transplant Program, Primary Children's Medical Center, Huntsman Cancer Institute, Salt Lake City, UT;

8. Colorado Blood Cancer Institute at Presbyterian/St. Luke's Medical Center, Denver, CO;

9. Clinical Statistics Program, Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA; and

10. Department of Biostatistics, University of Washington School of Public Health, Seattle, WA

Abstract

Key Points The HCT-CI stratifies patients into 3 groups for risks of grades 3 to 4 GVHD regardless of conditioning intensity, donor, or graft types. Comorbidity burden and development of grades 2 to 4 acute GVHD have cumulative effects on mortality rates.

Publisher

American Society of Hematology

Subject

Cell Biology,Hematology,Immunology,Biochemistry

Link

http://ashpublications.org/blood/article-pdf/124/2/287/1381277/287.pdf

Reference75 articles.

1. Effect of HLA incompatibility on graft-versus-host disease, relapse, and survival after marrow transplantation for patients with leukemia or lymphoma.;Anasetti;Hum Immunol,1990

2. High-resolution donor-recipient HLA matching contributes to the success of unrelated donor marrow transplantation.;Lee;Blood,2007

3. Acute graft-versus-host disease: analysis of risk factors after allogeneic marrow transplantation and prophylaxis with cyclosporine and methotrexate.;Nash;Blood,1992

4. Risk factors for acute graft-versus-host disease in histocompatible donor bone marrow transplantation.;Weisdorf;Transplantation,1991

5. Outcomes after matched unrelated donor versus identical sibling hematopoietic cell transplantation in adults with acute myelogenous leukemia.;Saber;Blood,2012

Cited by 79 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Impact of stem cell selection between bone marrow and peripheral blood stem cells for unrelated hematopoietic stem cell transplantation for hematologic malignancies: on behalf of the Donor/Source Working Group of the Japanese Society for Transplantation and Cellular Therapy;Cytotherapy;2024-02

2. The impact of pre-transplantation diabetes and obesity on acute graft-versus-host disease, relapse and death after allogeneic hematopoietic cell transplantation: a study from the EBMT Transplant Complications Working Party;Bone Marrow Transplantation;2023-12-07

3. Cardiovascular Events After Hematopoietic Stem Cell Transplant;JACC: CardioOncology;2023-12

4. Triple-Drug Graft-versus-Host Disease Prophylaxis after HLA-Matched Unrelated Donor Nonmyeloablative Allogenic Hematopoietic Stem Cell Transplantation;Transplantation and Cellular Therapy;2023-09

5. The Use of Prognostic Models in Allogeneic Transplants: A Perspective Guide for Clinicians and Investigators;Blood;2023-02-17